{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:19:31Z","timestamp":1791047971622,"version":"4.1.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastroenterology Clinics of North America"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1016\/j.gtc.2006.09.001","type":"journal-article","created":{"date-parts":[[2007,1,10]],"date-time":"2007-01-10T15:09:23Z","timestamp":1168441763000},"page":"883-893","source":"Crossref","is-referenced-by-count":22,"title":["Treatment of Immune-Mediated Extraintestinal Manifestations of Inflammatory Bowel Disease with Infliximab"],"prefix":"10.1016","volume":"35","author":[{"given":"Arthur","family":"Barrie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Plevy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gtc.2006.09.001_bib1","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2006.09.001_bib2","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2006.09.001_bib3","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2006.09.001_bib4","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn's disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2006.09.001_bib5","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2006.09.001_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1023\/A:1026629528233","article-title":"Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis","volume":"44","author":"Das","year":"1999","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gtc.2006.09.001_bib7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000083870","article-title":"Extraintestinal manifestations of Crohn's disease","volume":"71","author":"Juillerat","year":"2005","journal-title":"Digestion"},{"key":"10.1016\/j.gtc.2006.09.001_bib8","first-page":"711","article-title":"Extracolonic diagnoses in ulcerative colitis: an epidemiological study","volume":"85","author":"Monsen","year":"1990","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2006.09.001_bib9","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/0016-5085(79)90391-3","article-title":"National Cooperative Crohn's Disease Study: extraintestinal manifestations and perianal complications","volume":"77","author":"Rankin","year":"1979","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2006.09.001_bib10","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00005792-197609000-00004","article-title":"The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients","volume":"55","author":"Greenstein","year":"1976","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.gtc.2006.09.001_bib11","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0889-8553(01)00019-X","article-title":"Extraintestinal manifestations of inflammatory bowel disease","volume":"31","author":"Su","year":"2002","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.gtc.2006.09.001_bib12","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/j.1572-0241.2001.03756.x","article-title":"The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study","volume":"96","author":"Bernstein","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2006.09.001_bib13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00004836-199607000-00009","article-title":"Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients","volume":"23","author":"Veloso","year":"1996","journal-title":"J Clin Gastroenterol"},{"issue":"Suppl 4","key":"10.1016\/j.gtc.2006.09.001_bib14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2036.2004.02044.x","article-title":"Joint involvement in inflammatory bowel disease","volume":"20","author":"De Vos","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2006.09.001_bib15","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11938-003-0002-0","article-title":"Treatment of extraintestinal manifestations in inflammatory bowel disease","volume":"6","author":"Van Bodegraven","year":"2003","journal-title":"Curr Treat Options Gastroenterol"},{"key":"10.1016\/j.gtc.2006.09.001_bib16","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/ard.61.4.311","article-title":"Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation","volume":"61","author":"den Broeder","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.gtc.2006.09.001_bib17","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","article-title":"Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2006.09.001_bib18","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2006.09.001_bib19","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2006.09.001_bib20","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate","volume":"340","author":"Weinblatt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2006.09.001_bib21","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2006.09.001_bib22","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.gtc.2004.02.007","article-title":"Novel biologics in inflammatory bowel disease","volume":"33","author":"Papachristou","year":"2004","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.gtc.2006.09.001_bib23","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.semarthrit.2004.11.006","article-title":"The benefit\/risk profile of TNF-blocking agents: findings of a consensus panel","volume":"34","author":"Hochberg","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.gtc.2006.09.001_bib24","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2005.06.021","article-title":"The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study","volume":"129","author":"Bernstein","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2006.09.001_bib25","first-page":"307","article-title":"Crohn's disease associated with seropositive rheumatoid arthritis","volume":"15","author":"Toussirot","year":"1997","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.gtc.2006.09.001_bib26","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s00296-004-0467-8","article-title":"The effect of infliximab on extraintestinal manifestations of Crohn's disease","volume":"25","author":"Kaufman","year":"2005","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.gtc.2006.09.001_bib27","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/03009740510026698","article-title":"Infliximab in the treatment of extra-intestinal manifestations of Crohn's disease","volume":"34","author":"Rispo","year":"2005","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.gtc.2006.09.001_bib28","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/S0140-6736(00)03239-6","article-title":"Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms","volume":"356","author":"Van den Bosch","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2006.09.001_bib29","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/ard.59.6.428","article-title":"Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study","volume":"59","author":"Van den Bosch","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.gtc.2006.09.001_bib30","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/art.511","article-title":"Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy","volume":"46","author":"Van Den Bosch","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gtc.2006.09.001_bib31","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/ard.61.3.207","article-title":"Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up","volume":"61","author":"Kruithof","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.gtc.2006.09.001_bib32","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1136\/ard.2002.004879","article-title":"Infliximab in refractory spondyloarthropathies: a multicentre 38 week open study","volume":"62","author":"Collantes-Estevez","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.gtc.2006.09.001_bib33","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.semarthrit.2004.08.005","article-title":"Understanding the role of tumor necrosis factor inhibition in ankylosing spondylitis","volume":"34","author":"Davis","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.gtc.2006.09.001_bib34","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E","article-title":"Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab","volume":"43","author":"Brandt","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gtc.2006.09.001_bib35","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/rheumatology\/41.11.1280","article-title":"Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study","volume":"41","author":"Breban","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.gtc.2006.09.001_bib36","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2006.09.001_bib37","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/ard.2004.025130","article-title":"Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis","volume":"64","author":"Braun","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.gtc.2006.09.001_bib38","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1111\/j.1572-0241.2002.06064.x","article-title":"Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease","volume":"97","author":"Herfarth","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2006.09.001_bib39","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1136\/ard.2003.012450","article-title":"Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations","volume":"63","author":"Generini","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 4","key":"10.1016\/j.gtc.2006.09.001_bib40","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2036.2004.02055.x","article-title":"Review article: skin complications associated with inflammatory bowel disease","volume":"20","author":"Tavarela Veloso","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2006.09.001_bib41","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1136\/pgmj.2004.031633","article-title":"Important cutaneous manifestations of inflammatory bowel disease","volume":"81","author":"Trost","year":"2005","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.gtc.2006.09.001_bib42","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1080\/003655202320378338","article-title":"Pyoderma gangrenosum associated with Crohn disease: effect of TNF-alpha blockade with infliximab","volume":"37","author":"Ljung","year":"2002","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gtc.2006.09.001_bib43","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1046\/j.1365-2133.2003.05294.x","article-title":"Infliximab for peristomal pyoderma gangrenosum","volume":"148","author":"Mimouni","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.gtc.2006.09.001_bib44","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jaad.2004.10.006","article-title":"Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients","volume":"53","author":"Reichrath","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.gtc.2006.09.001_bib45","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1023\/B:DDAS.0000042245.20042.4f","article-title":"Treatment of pyoderma gangrenosum with infliximab in Crohn's disease","volume":"49","author":"Sapienza","year":"2004","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gtc.2006.09.001_bib46","first-page":"930","article-title":"Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody","volume":"137","author":"Tan","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.gtc.2006.09.001_bib47","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1080\/gas.37.7.863.865","article-title":"Favorable response to infliximab treatment in a patient with active Crohn disease and pyoderma gangrenosum","volume":"37","author":"Triantafillidis","year":"2002","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gtc.2006.09.001_bib48","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1111\/j.1572-0241.2003.07581.x","article-title":"Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease","volume":"98","author":"Regueiro","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2006.09.001_bib49","article-title":"Infliximab for the treatment of pyoderma gangrenosum: a randomised, double-blind placebo-controlled trial","author":"Brooklyn","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2006.09.001_bib50","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/00005176-200308000-00013","article-title":"Dermatologic manifestations of Crohn disease in children: response to infliximab","volume":"37","author":"Kugathasan","year":"2003","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.gtc.2006.09.001_bib51","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1046\/j.1365-2133.2003.05385.x","article-title":"Successful treatment with infliximab and methotrexate of pyostomatitis vegetans associated with Crohn's disease","volume":"149","author":"Bens","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.gtc.2006.09.001_bib52","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/17402520500134254","article-title":"Crohn's disease associated with Sweet's syndrome and Sjogren's syndrome treated with infliximab","volume":"12","author":"Foster","year":"2005","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.gtc.2006.09.001_bib53","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S1590-8658(03)00080-X","article-title":"Response of cutaneous Crohn's disease to infliximab and methotrexate","volume":"35","author":"Konrad","year":"2003","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.gtc.2006.09.001_bib54","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","article-title":"Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial","volume":"51","author":"Gottlieb","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.gtc.2006.09.001_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2005.12.012","article-title":"Anti-TNF therapies in the management of acute and chronic uveitis","author":"Hale","year":"2006","journal-title":"Cytokine"},{"key":"10.1016\/j.gtc.2006.09.001_bib56","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0161-6420(03)00406-8","article-title":"Infliximab in the treatment of refractory posterior uveitis","volume":"110","author":"Joseph","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.gtc.2006.09.001_bib57","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/bjo.2003.037192","article-title":"Anti-TNF-alpha therapy for sight threatening uveitis","volume":"89","author":"Lindstedt","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.gtc.2006.09.001_bib58","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ophtha.2005.09.037","article-title":"Retrospective case review of pediatric patients with uveitis treated with infliximab","volume":"113","author":"Rajaraman","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.gtc.2006.09.001_bib59","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(01)05497-6","article-title":"Effect of infliximab on sight-threatening panuveitis in Behcet's disease","volume":"358","author":"Sfikakis","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2006.09.001_bib60","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1572-0241.2002.05514.x","article-title":"Treatment of acute uveitis associated with Crohn's disease and sacroiliitis with infliximab","volume":"97","author":"Fries","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2006.09.001_bib61","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0161-6420(03)00721-8","article-title":"Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis","volume":"111","author":"Murphy","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.gtc.2006.09.001_bib62","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kel030","article-title":"Tumour necrosis factor {alpha} inhibitors in the treatment of childhood uveitis","author":"Saurenmann","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.gtc.2006.09.001_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2006.01.005","article-title":"Favorable response to high-dose infliximab for refractory childhood uveitis","author":"Kahn","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.gtc.2006.09.001_bib64","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/art.21197","article-title":"Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept","volume":"52","author":"Braun","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gtc.2006.09.001_bib65","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archopht.123.7.903","article-title":"A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes","volume":"123","author":"Suhler","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.gtc.2006.09.001_bib66","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/01.mpg.0000189347.32796.c5","article-title":"Granulomatous pneumonitis, sclerosing cholangitis, and pancreatitis in a child with Crohn disease: response to infliximab","volume":"42","author":"Silbermintz","year":"2006","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.gtc.2006.09.001_bib67","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1136\/ard.2004.032821","article-title":"Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis","volume":"64","author":"Germano","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.gtc.2006.09.001_bib68","article-title":"Serious liver disease induced by infliximab","author":"Tobon","year":"2006","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.gtc.2006.09.001_bib69","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nri1132","article-title":"The immunological and genetic basis of inflammatory bowel disease","volume":"3","author":"Bouma","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.gtc.2006.09.001_bib70","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s11926-996-0038-y","article-title":"Gut inflammation in the spondyloarthropathies","volume":"7","author":"Mielants","year":"2005","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.gtc.2006.09.001_bib71","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/path.1235","article-title":"Increase in lymphoid follicles and leukocyte adhesion molecules emphasizes a role for the gut in spondyloarthropathy pathogenesis","volume":"198","author":"Demetter","year":"2002","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.gtc.2006.09.001_bib72","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/path.1044","article-title":"Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy","volume":"196","author":"Baeten","year":"2002","journal-title":"J Pathol"},{"key":"10.1016\/j.gtc.2006.09.001_bib73","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1053\/j.gastro.2005.06.064","article-title":"A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease","volume":"129","author":"Schreiber","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2006.09.001_bib74","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nri1838","article-title":"B-cell targeting in rheumatoid arthritis and other autoimmune diseases","volume":"6","author":"Edwards","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.gtc.2006.09.001_bib75","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition","volume":"353","author":"Genovese","year":"2005","journal-title":"N Engl J Med"}],"container-title":["Gastroenterology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985530600077X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985530600077X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T17:46:59Z","timestamp":1587318419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088985530600077X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":75,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["S088985530600077X"],"URL":"https:\/\/doi.org\/10.1016\/j.gtc.2006.09.001","relation":{},"ISSN":["0889-8553"],"issn-type":[{"value":"0889-8553","type":"print"}],"subject":[],"published":{"date-parts":[[2006,12]]}}}